Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.

ABSTRACT:

Objective

Poly ADP-ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also induce severe organ system toxicities, including the hematological system. Our study aimed to extensively characterize the hematological toxicities of PARPis based on the real-world data.

Methods

Disproportionality analysis was used to evaluate the association between PARPis and hematotoxicity adverse events. Data were extracted from the US FDA Adverse Event Reporting System (FAERS) database between January 2015 and September 2021. The characteristics of PARPi-associated hematological toxicities, and the onset time and fatality proportion were further analyzed.

Results

Out of 24,045 adverse events reports, 4088 hem

SUBMITTER: Shu Y 

PROVIDER: S-EPMC9939145 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature